Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Short Course Treatment for Newly Diagnosed Rifampicin Resistant Tuberculosis
NCT04545788Unknown
- Sponsor
- Beijing Chest Hospital
- Start
- Aug 2020
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised trial of bedaquiline and linezolid in Tuberculosis (TB) (3 arms), sponsored by Beijing Chest Hospital. Primary endpoint: Culture of Mycobacterium tuberculosis in sputum at 1 year. Status: unknown.
02
Drugs
bedaquilinelinezolid
03
Conditions
Tuberculosis (TB)
Beyond the preview
Go deeper on NCT04545788.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545788.